Core Insights - Zhengye Biological (ZYBT) opened with a 3.17% increase, trading at $7.80 per share, with a total market capitalization of $370 million [1] - The company reported total revenue of 186 million RMB for the year ending December 31, 2024, representing a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company was 11.31 million RMB, reflecting a significant year-on-year decline of 64.04% [1] Company Overview - Zhengye Biological Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]
正业生物上涨3.17%，报7.8美元/股，总市值3.70亿美元